University of California San Francisco

Emily Bergsland, MD

Emily Bergsland, M.D.
Emily Bergsland, MD

Professor of Clinical Medicine
Division of Hematology Oncology
Department of Medicine
Ernest Rosenbaum, MD Endowed Chair of Medical Oncology

Address

550 16th Street, #6804
San Francisco, CA 94158
United States

Email: [email protected]

Biography

Emily Bergsland, MD is a medical oncologist at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center who specializes in gastrointestinal malignancies. She is a Professor of Medicine, Director of the UCSF Center for Neuroendocrine Tumors, and serves as Associate Director for Education for the UCSF Helen Diller Family Comprehensive Cancer Center. Dr. Bergsland leads a clinical-translational research program focused on neuroendocrine neoplasms of all grades, which includes clinical trials and collaborative studies related to biomarkers, imaging and clinical outcomes. She is past president of the North American Neuroendocrine Tumor Society, a longstanding member of the NCCN Neuroendocrine Tumor Guidelines panel, and past chair of the NET Task Force of the NCI Gastrointestinal Steering Committee.

Education

Institution Degree Dept or School End Date
University of California Diversity, Equity, and Inclusion Champion Training 2019
University of California (UCSF) Molecular Medicine Training Program 06/1998
University of California (UCSF) Fellowship Medical Oncology 06/1995
University of California (UCSF) Chief Residency 06/1993
University of California (UCSF) Residency Internal Medicine 06/1992
University of Minnesota MD Medicine 06/1989
University of Wisconsin BS Biochemistry/Molecular Biology 05/1985

Board Certifications

American Board of Internal Medicine
American Board of Internal Medicine: Medical Oncology - Subspecialty

Clinical Expertise

Colon Cancer
Esophageal Cancer
Liver Cancer
Lynch Syndrome
Pancreatic Cancer
Rectal Cancer
Stomach Cancer

Grants and Funding

  • UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology | NIH | 2021-07-01 - 2026-06-30 | Role: Principal Investigator

Research Interests

Angiogenesis Inhibitors 
Pancreatic Neoplasms 
Vascular Endothelial Growth Factor
Colorectal Neoplasms 
Neuroendocrine Tumors 

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Patterns of Progression After Peptide Receptor Radiopharmaceutical Therapy.
    Moradpour M, Moradi Tochayi A, Houshmand S, Nwihim S, Jiang F, Yadav S, Lindsay S, Bergsland EK, Hope TA| | PubMed
  2. Characterization of small intestinal neuroendocrine tumorlets.
    Yogo A, Akanuma N, Kim GE, Paciorek A, Zhang L, Le P, Hirose K, Corvera CU, Bergsland EK, Nakakura EK| | PubMed
  3. ACR Appropriateness Criteria® Staging and Follow-Up of Pancreatic Neuroendocrine Tumors.
    Expert Panel on Gastrointestinal Imaging, Yacoub JH, Yano M, Chang KJ, Bergsland E, Bhosale PR, Cash BD, Chernyak V, Gupta A, Hallet J, Halpern J, Magnetta M, Noronha CF, Refaat T, Korngold EK| | PubMed
  4. Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.
    Choucair A, Zdunek A, Liao M, Bodei L, Deandreis D, Das J, Barbe R, Bergsland E, Geyer S, Bidault F, Garcia G, Yeh R, Balleyguier C, Lassau N, Dercle L, Ammari S| | PubMed
  5. Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.
    de Mestier L, Halfdanarson TR, Apostolidis L, Koumarianou A, Hernando J, Riechelmann R, Bergsland EK, Cingarlini S, Shaheen S, Crona J, Kreutzfeldt S, Mosalem O, Al-Toubah T, Cros J, Strosberg JR| | PubMed
  6. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).
    Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg JR, Venook AP, O'Reilly EM, Meyerhardt JA| | PubMed
  7. 4D-MRI at 0.55T for internal target volume delineation in liver radiation therapy planning.
    Miao X, Su P, Ohliger MA, Yang Y, Pang J, Hotca AE, Hope TA, Hong CW, Bergsland EK, Feng M, Scholey JE| | PubMed
  8. Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study.
    Riechelmann RP, Torrezan GT, Bergsland E, Raj N, Strosberg J, Moon F, Felismino TC, Knappskog S, Trevizani E, Cingarlini S, Sorbye H| | PubMed
  9. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms.
    Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies Consortium Group| | PubMed
  10. Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms.
    Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, Gunderson C, Bergsland E, Strosberg JR, Halfdanarson TR, Metz DC, Kunstman JW, Kunz PL, Gangi A, Peritoneal Surface Malignancies (PSM) Consortium Group| | PubMed